Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of…
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in…
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom)…
RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh successfully…
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.…
July 29, 2025 09:01 ET | Source: Windtree Therapeutics Investors choose to redeem or convert the majority of Series C…
July 29, 2025 09:00 ET | Source: NewGenIvf Limited The new cytometry technology enhances accessibility, safety, and efficiency in sperm-sorting…
OCALA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the pricing…
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company…
July 28, 2025 12:24 ET | Source: Can-Fite BioPharma Ltd. $5.0 million upfront with up to an additional $10.0 million…